Helicobacter pylori infection
Conditions
Interventions
Control group:Rabeprazole 10mg 3/day + Amoxicillin 1000mg 3/day for 14 days
Experimental group :Vonolasan 20mg 2/day + Amoxicillin 1000mg 3/day for 10 days.
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients, aged between 18-65 years; 2. Patients diagnosed as HP infection by C13/C14 urea breath test or immunohistochemical staining of biopsy samples; 3. Patients with indications of HP eradication and no antagonistic factors; 4. Patients who have not received HP eradication treatment before; 5. Patients who did not take antibiotics, bismuth and antibacterial traditional Chinese medicine 4 weeks before the treatment, and those who did not take PPI, H2 receptor antagonists and other drugs that affect the activity of HP 2 weeks before the treatment; 6. Patients were informed and agreed to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, liver, lung, and kidney dysfunction and low immunity (such as HIV infection, under cancer treatment); 2. Patients with penicillin or program-related drug allergy contraindications; 3. Patients with mental illness and communication disorder; 4. Pregnant and lactating patients; 5. Patients with serious gastrointestinal diseases, such as tumors, gastrointestinal bleeding, Zollinger-Ellison syndrome, etc; 6. Patients who are participating in other clinical trials; 7. The researchers think it is not suitable for the patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Compliance; | — |
Countries
China
Contacts
Public ContactLi Peiyuan
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed